Patent US10842867

(i) a purified surface antigen, prepared from a cell culture-grown human influenza virus; and

(ii) an adjuvant comprising an oil-in-water emulsion, wherein the composition is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.

(i) a purified surface antigen, prepared from a cell culture-grown human influenza virus; and

 

(ii) an adjuvant comprising an oil-in-water emulsion, wherein the composition is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.

(i) a first kit component comprising a purified surface antigen, prepared from a cell culture-grown human influenza virus; and

 

(ii) a second kit component comprising an adjuvant comprising an oil-in-water emulsion, wherein the first kit component is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.

(i) a purified surface antigen, prepared from a cell culture-grown human influenza virus; and

(ii) an adjuvant comprising an oil-in-water emulsion and a tocopherol, wherein the composition is free from chicken DNA, ovalbumin and ovomucoid, and wherein the emulsion includes about 4.3% squalene by weight, about 0.5% polysorbate 80 by weight and about 0.48% sorbitan trioleate by weight and has sub-micron droplets.